EDSA is expected to report earnings to rise 56.70% to -15 cents per share on December 13
Q3'23
Est.
$-0.16
Q2'23
Beat
by $0.06
Q1'23
Est.
$-0.12
Q4'22
Beat
by $0.05
Q3'22
Beat
by $0.03
The last earnings report on August 11 showed earnings per share of -10 cents, beating the estimate of -15 cents. With 2.58K shares outstanding, the current market capitalization sits at 7.14M.
a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs.